DEC 04, 2020 8:00 AM PST
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar

Analytical Limitations of HbA1c: Factors to consider when choosing an HbA1c Methodology

Sponsored by: Sebia, Inc.
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Medical Director: Special Chemistry and Endocrinology - Assistant Professor, University of Utah School of Medicine
    Biography

      Dr. Kelly Doyle is a fellow in the National Academy of Clinical Biochemistry and is a board certified clinical chemist. His interests involve the clinical application and implementation of mass spectrometry, emerging biomarkers, toxicology, endocrinology, and laboratory best practice. He has a special interest in training clinical chemistry fellows and teaching principles of laboratory medicine to pathology residents and medical students.

    • Director, Diabetes Diagnostic Laboratory (DDL) - Network Coordinator, NGSP
      Biography

        Randie Little, PhD is a Research Professor in the Departments of Pathology & Anatomical Sciences and Child Health at the University of Missouri and is Director of the Diabetes Diagnostic Laboratory (DDL). Dr. Little is the coordinator of the NGSP (National Glycohemoglobin Standardization Program) network, a member of the NGSP Steering Committee and also coordinates NIDDK- sponosored C-peptide Standardization activities. The DDL, is the primary site of the NGSP, an international program for standardization of HbA1c which is the most important test used to assess glycemic control in patients with diabetes. The NGSP maintains a worldwide laboratory network with reference method results that are based on landmark clinical trial data. The program certifies manufacturer methods for HbA1c and also certifies and monitors laboratories doing large studies and clinical trials where measurement of HbA1c is a key variable. The NGSP network assigns values to the accuracy based College of American Pathologists (CAP) HbA1c survey. Related research includes examination of stability of HbA1c and interferences (e.g. from Hb variants) with different assay methods. Standardization of c‐peptide is also in progress at the DDL; the DDL has established an LS/MS reference method for c‐peptide as well as a complete traceability chain for C-peptide.

      • Senior Investigator - Chief, Clinical Chemistry Service - NIH
        Biography

          David Sacks is Senior Investigator and Chief of Clinical Chemistry Service at the National Institutes of Health, Adjunct Professor of Medicine at Georgetown University, Clinical Professor of Pathology at George Washington University and Honorary Professor of Clinical Laboratory Sciences at the University of Cape Town. He received his medical training at the University of Cape Town. He completed residencies in Internal Medicine at Georgetown University affiliated hospitals in Washington, D.C. and in Clinical Pathology at Washington University, St. Louis. After fellowship training in Clinical Chemistry at Washington University, he spent 21 years in the Department of Pathology at Harvard Medical School.


        Abstract

        DATE: December 4th, 2020

        TIME:  8:00am PT

         

        With many methods available for HbA1c testing, how do you choose a method that’s best for your laboratory? The incidence and prevalence of diabetes mellitus is on the rise, and so is the use of HbA1c in the clinical laboratory. HbA1c is routinely used as the gold standard test to monitor, diagnose, and manage diabetic patients. However, there are several limitations to HbA1c as an assay in diabetes screening, including methodology, analytical interference, and biological interference. Different methodologies exist today to measure HbA1c such as immunoassay, enzymatic, HPLC and capillary electrophoresis. While many commercial methodologies are standardized, what are the limitations to each of these methods? What do you need to consider when choosing an HbA1c method for your laboratory?

         

        Learning Objectives:

        • Review methods available for measuring HbA1c in the clinical laboratory.
        • Understand standardization of measuring HbA1c.
        • Examine clinical utility of different HbA1c assays.
        • Evaluate factors to consider when selecting an HbA1c method in your laboratory.

         

        Webinars will be available for unlimited on-demand viewing after live event.

         

        LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


        Show Resources
        You May Also Like
        SEP 10, 2020 9:00 AM PDT
        C.E. CREDITS
        SEP 10, 2020 9:00 AM PDT
        Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
        JUL 22, 2020 10:00 AM PDT
        C.E. CREDITS
        JUL 22, 2020 10:00 AM PDT
        DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
        SEP 03, 2020 9:00 AM PDT
        C.E. CREDITS
        SEP 03, 2020 9:00 AM PDT
        DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
        JUN 30, 2020 9:00 AM PDT
        C.E. CREDITS
        JUN 30, 2020 9:00 AM PDT
        DATE: June 30, 2020 TIME: 9:00am PDT, 12:00pm EDT QC laboratories perform a critical role in demonstrating pharmaceutical products are consistently manufactured, safe, potent, and pure. At t...
        JUN 23, 2020 10:00 AM PDT
        C.E. CREDITS
        JUN 23, 2020 10:00 AM PDT
        DATE: June 23, 2020 TIME: 10:00am PT Human mesenchymal stromal or stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach for many diseases, s...
        C.E. CREDITS
        This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
        Loading Comments...
        Show Resources
        Event Countdown
        • 0 Days
        • 0 Hours
        • 0 Minutes
        • 0 Seconds
        Attendees
        • See more